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Abstract 
Best macular dystrophy is reported to be rare in Africans. It is a hereditary disease that starts 
in childhood and progresses through some stages before visual symptoms occur. This case 
report presents a 43-year-old Nigerian with the disease and stresses the importance of 
regular eye exams of patients and relatives to detect changes such as choroidal neovascular 
membrane amenable to treatment. 
 
Case Presentation 
A.T., a 43-year-old Nigerian lady, presented to the Eye Clinic of the University College Hospital, 
Ibadan with gradual blurring of vision in both eyes for 4 years. Two of her siblings were reported to 
have similar complaints. Ocular examination showed unaided visual acuity of 6/12 OU corrected to 
6/9 in both eyes. Near vision was normal. The anterior segment examination was not remarkable. IOP 
was 13 mm Hg in both eyes. Dilated fundoscopy showed a well circumscribed cystic fovea lesion with 
a fluid level and an atrophic center in the right eye, while the left eye showed a scar in the macula 
(fig. 1 and fig. 2). The systemic examination was not remarkable. An assessment of Best macular 
dystrophy was made. The patient was prescribed with spectacles, counseled and placed on close 
observation with Amslers grid for the development of choroidal neovascular membrane that will 
require urgent treatment. 
Discussion 
This is probably the first case of Best macular dystrophy to be reported in Ibadan, 
Nigeria and possibly Sub-Saharan Africa to the best of the author’s knowledge. The 
disease is a hereditary macular dystrophy first described by Best in 1905 [1]. It has also 
been reported in Caucasians and Asians [2], the other cases seen in African Americans 
were associated with sickle cell trait [3]. The disease starts in childhood with a  
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characteristic macular lesion resembling an egg yolk. It progresses through some stages 
before visual symptoms become apparent. Table 1 describes these stages [4]. 
Pathophysiology 
The pathophysiology of Best’s disease is explained by abnormality in the retinal 
pigment epithelium (RPE) with resultant abnormal ionic transport leading to the 
accumulation of lipofuscin in the RPE cells and sub-RPE space in the macular area. 
Degeneration of RPE cells can occur [5, 6]. 
Vision is good in the early stages of the disease. The vitelliruptive stage may herald 
visual deterioration which becomes worse in the atrophic stage due to the presence of 
choroidal neovascular membrane. Our patient presented with the early stages of the 
disease, hence the good visual acuity. The patient will be under observation and follow-
up so as to detect changes amenable to treatment. Choroidal neovascular membrane 
(CNVM) from Best’s disease has been reported to respond well to intravitreal antiVEGF 
[7, 8]. Fundus flourescein angiography is essential in confirming the presence of CNVM 
and should be done when patient presents with sudden deterioration in vision. If a 
CNVM develops, then a corresponding area of hyperfluorescence with leakage will be 
found. 
Since the disease is an autosomal dominant disorder, other family members will 
benefit from regular fundus examinations, and Amslers grid is a valuable tool for 
monitoring central vision. An electrophysiologic test such as electrooculogram (EOG) is 
specific for confirming the presence of the disease in relatives even in the absence of 
clinical signs and symptoms. A severe decrease occurs in light response, reflected by an 
Arden (light-peak/dark-trough) ratio of 1.1–1.5 (the normal Arden ratio is 1.8) [9]. The 
full-field electroretinogram (ERG) result is normal in Best’s disease. A focal ERG or 
multifocal ERG, concentrating on macular function, reveals abnormal function 
corresponding to the area of anatomical disruption [10]. 
Conclusion 
This is a report of Best macular dystrophy in Ibadan, Sub-Saharan Africa. Regular 
eye exams are advised for families with the disease. Other so-called rare ocular 
diseases may not be so after all. 
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Table 1. Stages of Best macular dystrophy (modified) [4] 
            Stage of disease  Findings  Expected visual acuity 
                I  Pre-vitelliform  Speckled fine pigmentary disturbance in the macula is seen  6/6 
                II   Vitelliform  Egg-yolk lesion composed of a round, homogeneous, 
opaque yellow lesion with discrete margins measuring 
approximately 1 disc diameter in size 
6/6–6/12 
                III  Pseudo-
hypopyon 
The yellow material within the vitelliform cyst develops a 
fluid level, resulting in the appearance of a pseudohypopyon 
6/6–6/36 
                IV  Vitelliruptive/ 
atrophic 
Advanced disease with an atrophic macular pigment 
epithelium (stage IVa), fibrous scarring (stage IVb), or 
subretinal neovascularization (stage IVc) 
6/6–6/60, CNVM may 
be associated with VA 
less than 6/60 
                 
 
 
 
 
Fig. 1. Right eye of patient with the pseudohypopyon stage of Best’s disease. 
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Fig. 2. Left eye of patient with the atrophic stage of Best’s disease. 
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